Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
about
Effects of statins on cancer mortality and progression: A systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals.Impact of statin use on cancer recurrence and mortality in breast cancer: A systematic review and meta-analysis.Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancerDysregulation of the mevalonate pathway promotes transformationStatins and breast cancer prognosis: evidence and opportunities.Bioinformatic identification of proteins with tissue-specific expression for biomarker discoverySystematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifenMalignant fibrous histiocytoma of visceral organs: clinicopathologic features and diagnostic value of ezrin and HMG-CoA reductase.Various types and management of breast cancer: an overviewTumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.FKBPL: a marker of good prognosis in breast cancer.HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes.Statins and risk of breast cancer recurrence.High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer.HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcomeThe emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL.Pre-diagnostic statin use, lymph node status and mortality in women with stages I-III breast cancer.Functional characterization of AMP-activated protein kinase signaling in tumorigenesis.The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study.The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancer.Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.Cartilage oligomeric matrix protein contributes to the development and metastasis of breast cancer.Stromal regulation of prostate cancer cell growth by mevalonate pathway enzymes HMGCS1 and HMGCR.Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database.Interactions Between Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients
P2860
Q30241078-09DDF067-1AE4-4E42-8EEA-B3CA6CBBCC6AQ30250324-C5B9BAD2-9F08-498D-87F5-759A12B7A331Q33548538-807F8F7D-4E4C-4668-BFF9-D0D05966B554Q34093736-557CA09A-BB1E-4A81-999D-75C9D5A88982Q34206487-4305A7D8-4B7B-4B29-904F-E53A5D6CF854Q34239193-59AB6214-FA89-4EFC-B2E3-91465BBDFDF4Q34644894-B99FABA3-A559-4DFD-A827-11F8A3E2AE48Q35029556-B286C9A3-CA75-4D77-B33C-2F43C13D9BD4Q35632204-C4F6C6E1-B5F5-4520-A5F7-EC5FA1130E69Q35664703-243145D8-A350-48D2-A520-926AA12BC6B2Q35673791-F7031A70-26EB-40CD-95AD-1BD7BB72260DQ35828542-51C10964-7A05-470C-8A65-D651F99108E2Q37319005-C070CA78-30E6-4DFE-A93D-CE22B1003BEBQ37407449-85DEE648-0211-4FED-8E52-3AAC9D4731E7Q37644912-3F98D6AD-3D55-4305-84A2-177035775EFCQ37724074-F9E2099E-621B-4FE3-A6BD-0EB712C55762Q37856424-B506E033-22F6-4BD8-91C0-84EEAA9E0BCCQ38673155-AFC3D136-B67C-43B0-9384-20DBBC76BD91Q38807302-558737B4-7E57-4615-9AB4-56A9F68CBD81Q39201898-CF870691-2B47-44AB-B767-84F50A72A410Q39317705-B3C0FCC7-815C-4E97-B8F7-9EB0E1C404B3Q39433453-8DEFFC96-61E8-411D-94FF-BE3909EE19C7Q39455228-056EE454-2EB2-4543-B43E-B45DBEE867FFQ40513874-C7F6689F-3FF9-4178-A7E8-2329819A005CQ44322819-7AFF6ACD-BCE8-44BA-BEB2-F481FB03329AQ47372688-3D01FCC7-F628-4D50-8664-74CE5832249EQ58122649-1E934E96-9441-424E-BAE0-3BBB3236C7FC
P2860
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prognostic impact of tumour-sp ...... sion in primary breast cancer.
@en
Prognostic impact of tumour-sp ...... sion in primary breast cancer.
@nl
type
label
Prognostic impact of tumour-sp ...... sion in primary breast cancer.
@en
Prognostic impact of tumour-sp ...... sion in primary breast cancer.
@nl
prefLabel
Prognostic impact of tumour-sp ...... sion in primary breast cancer.
@en
Prognostic impact of tumour-sp ...... sion in primary breast cancer.
@nl
P2860
P50
P356
P1476
Prognostic impact of tumour-sp ...... sion in primary breast cancer.
@en
P2093
Donal J Brennan
Lisa Rydén
P2860
P2888
P356
10.1186/BCR2146
P577
2008-09-22T00:00:00Z
P5875
P6179
1049439878